trial · primary record
JADE101
IgA Nephropathy
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2029-04 |
| Primary endpoint | Incidence of treatment-emergent adverse events (safety and tolerability) |
| Registry ID | NCT07541287 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:37.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07541287
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Jade101 · compound